ACHV Form 3: Craig Donnelly reports 52,372 shares and 47,500 options
Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards.
Rhea-AI Filing Summary
Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards. One option covers 25,000 shares exercisable beginning 03/14/2033 at $4.53; the other covers 22,500 shares exercisable beginning 01/22/2034 at $4.55. Vesting schedules for each grant are disclosed in the filing.
Positive
- Initial Section 16 disclosure filed for an officer, improving transparency
- Detailed vesting schedules and exercise prices for both option grants were provided
Negative
- None.
Insights
TL;DR: Officer disclosed modest direct holdings and standard employee option grants; no immediate dilutive impact.
The Form 3 reports direct ownership of 52,372 shares and two option grants totaling 47,500 shares with exercise prices near $4.53–$4.55 and multi-year vesting. This is a routine Section 16 initial disclosure that provides transparency on insider holdings and potential future dilution as options vest and become exercisable. No cash, debt, or revenue figures are included.
TL;DR: Filing meets Section 16 disclosure requirements and details vesting mechanics for governance oversight.
The submission documents the reporting officer's beneficial ownership and the vesting schedule for two option awards, allowing stakeholders to track insider incentives and timing of potential exercises. The signature is by attorney-in-fact, consistent with procedural practice. No governance issues or departures are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Sock | -- | -- | -- |
Footnotes (2)
- F1. 25% of the options became exercisable on March 1, 2024 and the remainder vest in thirty-six equal monthly installments thereafter.
- F2. The options vest as to one-third of the award on January 22, 2025 and thereafter in equal monthly installments over 24 months.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Craig Donnelly report on the ACHV Form 3?
What are the exercise prices and exercisable dates of the options reported on ACHV Form 3?
How do the reported options vest according to the filing?
When was the event requiring this Form 3 reported?
Does the Form 3 disclose any indirect ownership or other holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.